4jn2
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | + | ==An Antidote for Dabigatran== | |
| - | === | + | <StructureSection load='4jn2' size='340' side='right' caption='[[4jn2]], [[Resolution|resolution]] 1.71Å' scene=''> |
| - | { | + | == Structural highlights == |
| + | <table><tr><td colspan='2'>[[4jn2]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4JN2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4JN2 FirstGlance]. <br> | ||
| + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=C24:3-({2-[(4-CARBAMIMIDOYL-PHENYLAMINO)-METHYL]-3-METHYL-3H-BENZOIMIDAZOLE-5-CARBONYL}-PYRIDIN-2-YL-AMINO)-PROPIONIC+ACID+ETHYL+ESTER'>C24</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | ||
| + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4jn1|4jn1]]</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4jn2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4jn2 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4jn2 RCSB], [http://www.ebi.ac.uk/pdbsum/4jn2 PDBsum]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Key points We present an antidote for dabigatran that effectively reverses its anticoagulative effect in human plasma in vitro and in rats in vivo.The antidote shares structural features with thrombin in the mode of binding, but has no activity in coagulation tests. | ||
| - | + | A specific antidote for dabigatran: functional and structural characterization.,Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T Blood. 2013 Mar 8. PMID:23476049<ref>PMID:23476049</ref> | |
| - | + | ||
| - | == | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> |
| - | + | </div> | |
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
[[Category: Mus musculus]] | [[Category: Mus musculus]] | ||
| - | [[Category: Nar, H | + | [[Category: Nar, H]] |
| - | [[Category: Schiele, F | + | [[Category: Schiele, F]] |
[[Category: Dabigatran]] | [[Category: Dabigatran]] | ||
[[Category: Igg fragment binding dabigatran]] | [[Category: Igg fragment binding dabigatran]] | ||
[[Category: Immune system-inhibitor complex]] | [[Category: Immune system-inhibitor complex]] | ||
Revision as of 15:10, 21 December 2014
An Antidote for Dabigatran
| |||||||||||
